Literature DB >> 10656610

Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.

W P Mielicki1, M Tenderenda, P Rutkowski, K Chojnowski.   

Abstract

The activity of cancer procoagulant (CP), prothrombin time (PT), activated partial thromboplastin time (APTT), the concentration of thrombin-antithrombin complexes (TAT) and the concentration of fibrinogen were analysed in blood of breast cancer patients scheduled for surgery. The serum level of CP activity was dependent on the stage of the disease. The CP activity was increased in 72% of patients with an early stage of cancer and in only 20% of patients with an advanced stage of the disease when compared to the baseline level for non-cancer controls. In all patients PT remained at normal levels (80-120%). There was no significant change in APTT (27-39 s) in early stage cancer patients. Only one patient with advanced cancer had APTT shortened to 23 s. Also one advanced stage patient had significantly elevated level of TAT (14.96 microg/l); in all other patients the concentration of TAT remained at normal levels (1-4.1 microg/l). Forty-four percent of early stage cancer patients and 22% of advanced cancer patients had an elevated level of fibrinogen (Fg) ( > 350 mg%). However, there was no correlation between the level of Fg and the CP activity (P > 0.05). The data suggest that: (1) serum CP activity increases at the early stage of breast cancer and decreases down to the normal level in the advanced stage of the disease; (2) there is no evidence of blood clotting activation in the early stage breast cancer patients; and (3) CP does not facilitate the activation of coagulation in the breast cancer patients or the level of such activation is below the sensitivity of assays used in the experiment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10656610     DOI: 10.1016/s0304-3835(99)00230-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  6 in total

1.  Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.

Authors:  Mark Wahrenbrock; Lubor Borsig; Dzung Le; Nissi Varki; Ajit Varki
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 2.  Epidemiology and pathophysiology of cancer-associated thrombosis.

Authors:  S Noble; J Pasi
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

3.  Plasma d-dimer level correlated with advanced breast carcinoma in female patients.

Authors:  Basim Rassam Ghadhban
Journal:  Ann Med Surg (Lond)       Date:  2018-10-26

Review 4.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

5.  The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression.

Authors:  Joanna Kołodziejczyk; Michał B Ponczek
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

6.  Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.

Authors:  C C Kirwan; G McDowell; C N McCollum; S Kumar; G J Byrne
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.